EVOTEC ORD SHS
EVOTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$591.06M
Close$
$-5.92
278.1% downside
Current Fair Value
278.1% downsideOvervalued by 278.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $591.06 Million |
|---|---|
| Enterprise Value | $718.57 Million |
| Earnings per Share | $-0.58 |
| Beta | 1.26 |
| Outstanding Shares | 177,763,790 |
Return
| Return on Equity | -30.04% |
|---|---|
| Return on Assets | -12.70% |
| Return on Invested Capital | -10.09% |
Valuation & Multiples
| P/E Ratio | -2.54 |
|---|---|
| PEG | -28.05 |
| Price to Sales | 0.83 |
| Price to Book Ratio | 1.11 |
| Enterprise Value to Revenue | 1 |
| Enterprise Value to EBIT | -5.65 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.66 |
| Debt to Equity | 0.71 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.36
Consensus analyst estimateRevenue Estimate
$167.05 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 14, 2027
EPS Estimate
$-0.27
Consensus analyst estimateRevenue Estimate
$156.94 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Evotec SE
4,553 employees
CEO: Werner Lanthaler
Evotec SE operates as a global collaborative partner for the pharmaceutical and biotechnology industries, focusing on drug discovery and development. The firm is actively engaged in advancing medicinal products spanning a diverse range o...